Taku Kato1, Kosuke Mizutani2, Koji Kameyama2, Kyojiro Kawakami3, Yasunori Fujita3, Keita Nakane4, Yusuke Kanimoto4, Hidetoshi Ehara5, Hiroyasu Ito6, Mitsuru Seishima6, Takashi Deguchi2, Masafumi Ito7. 1. Department of Informative Clinical Medicine, Gifu University Graduate School of Medicine, Gifu, Gifu, Japan; Department of Urology, Gifu University Graduate School of Medicine, Gifu, Gifu, Japan. 2. Department of Urology, Gifu University Graduate School of Medicine, Gifu, Gifu, Japan. 3. Research Team for Mechanism of Aging, Tokyo Metropolitan Institute of Gerontology, Itabashi-ku, Tokyo, Japan. 4. Department of Urology, Chutoen General Medical Center, Kakegawa, Shizuoka, Japan. 5. Department of Urology, Murakami Memorial Hospital, Asahi University, 3-23 Hashimoto-cho, Gifu, Gifu, Japan. 6. Department of Informative Clinical Medicine, Gifu University Graduate School of Medicine, Gifu, Gifu, Japan. 7. Research Team for Mechanism of Aging, Tokyo Metropolitan Institute of Gerontology, Itabashi-ku, Tokyo, Japan. Electronic address: mito@tmig.or.jp.
Abstract
OBJECTIVES: Docetaxel is used as the first-line chemotherapy for castration-resistant prostate cancer (CRPC), but docetaxel resistance occurs in part owing to induction of P-glycoprotein (P-gp) encoded by multidrug resistance protein 1 (MDR1) gene. A recently developed taxane-cabazitaxel-has poor affinity for P-gp and is thereby effective in docetaxel-resistant CRPC. It has been recently demonstrated that exosomes in the body fluids could serve as a diagnostic marker because they contain proteins and RNAs specific to the cells from which they are derived. In this study, we aimed to investigate if P-gp in blood exosomes could be a marker to diagnose docetaxel resistance and select a taxoid for patients with CRPC. METHODS AND MATERIALS: Exosomes were isolated by differential centrifugation from docetaxel-resistant prostate cancer (PC-3) cells (PC-3R) and their parental PC-3 cells and from the serum of patients. Silencing of P-gp was performed by small interfering RNA transfection. Protein expression was examined by Western blot analysis. Viability of cells treated with docetaxel or cabazitaxel was determined by water soluble tetrazolium salt (WST) assay. RESULTS: The level of P-gp was higher in exosomes as well as cell lysates from PC-3R cells than in those from PC-3 cells. Cabazitaxel effectively killed PC-3R cells, and MDR1 knockdown improved the sensitivity of PC-3R cells to docetaxel but not to cabazitaxel. The P-gp level in blood exosomes was relatively higher in clinically docetaxel-resistant patients than in therapy-naïve patients. CONCLUSIONS: Our results suggest that detection of P-gp in blood exosomes, which is involved in resistance to docetaxel but not to cabazitaxel, could be useful to diagnose docetaxel resistance and select an appropriate taxoid for patients with CRPC-docetaxel or cabazitaxel.
OBJECTIVES:Docetaxel is used as the first-line chemotherapy for castration-resistant prostate cancer (CRPC), but docetaxel resistance occurs in part owing to induction of P-glycoprotein (P-gp) encoded by multidrug resistance protein 1 (MDR1) gene. A recently developed taxane-cabazitaxel-has poor affinity for P-gp and is thereby effective in docetaxel-resistant CRPC. It has been recently demonstrated that exosomes in the body fluids could serve as a diagnostic marker because they contain proteins and RNAs specific to the cells from which they are derived. In this study, we aimed to investigate if P-gp in blood exosomes could be a marker to diagnose docetaxel resistance and select a taxoid for patients with CRPC. METHODS AND MATERIALS: Exosomes were isolated by differential centrifugation from docetaxel-resistant prostate cancer (PC-3) cells (PC-3R) and their parental PC-3 cells and from the serum of patients. Silencing of P-gp was performed by small interfering RNA transfection. Protein expression was examined by Western blot analysis. Viability of cells treated with docetaxel or cabazitaxel was determined by water soluble tetrazolium salt (WST) assay. RESULTS: The level of P-gp was higher in exosomes as well as cell lysates from PC-3R cells than in those from PC-3 cells. Cabazitaxel effectively killed PC-3R cells, and MDR1 knockdown improved the sensitivity of PC-3R cells to docetaxel but not to cabazitaxel. The P-gp level in blood exosomes was relatively higher in clinically docetaxel-resistant patients than in therapy-naïve patients. CONCLUSIONS: Our results suggest that detection of P-gp in blood exosomes, which is involved in resistance to docetaxel but not to cabazitaxel, could be useful to diagnose docetaxel resistance and select an appropriate taxoid for patients with CRPC-docetaxel or cabazitaxel.
Authors: Bodine P S Belderbos; Koen G A M Hussaarts; Leonie J van Harten; Esther Oomen-de Hoop; Peter de Bruijn; Paul Hamberg; Robbert J van Alphen; Brigitte C M Haberkorn; Martijn P Lolkema; Ronald de Wit; Robert J van Soest; Ron H J Mathijssen Journal: Br J Clin Pharmacol Date: 2019-03-21 Impact factor: 4.335
Authors: Alan P Lombard; Chengfei Liu; Cameron M Armstrong; Vito Cucchiara; Xinwei Gu; Wei Lou; Christopher P Evans; Allen C Gao Journal: Mol Cancer Ther Date: 2017-07-11 Impact factor: 6.261
Authors: Stephanie N Dorman; Katherina Baranova; Joan H M Knoll; Brad L Urquhart; Gabriella Mariani; Maria Luisa Carcangiu; Peter K Rogan Journal: Mol Oncol Date: 2015-08-22 Impact factor: 6.603
Authors: E E Perez-Guerrero; L Gonzalez-Lopez; J F Muñoz-Valle; J C Vasquez-Jimenez; M Ramirez-Villafaña; E N Sanchez-Rodriguez; S R Gutierrez-Ureña; S Cerpa-Cruz; E A Aguilar-Chavez; E G Cardona-Muñoz; M L Vazquez-Villegas; A M Saldaña-Cruz; N A Rodriguez-Jimenez; N S Fajardo-Robledo; J I Gamez-Nava Journal: Inflammopharmacology Date: 2018-09-12 Impact factor: 4.473